Jump to content

EB-003

Add links
From Wikipedia, the free encyclopedia
EB-003
Clinical data
Other namesEB003
Drug classNon-hallucinogenic serotonin 5-HT1A and 5-HT2A receptor agonist

EB-003 is a non-hallucinogenic serotonin 5-HT1A and 5-HT2A receptor agonist and psychoplastogen which is under development for the treatment of depressive disorders and anxiety disorders.[1][2][3][4] It is not a serotonin 5-HT2B receptor agonist.[4][5] The drug is being developed by Enveric Biosciences.[1][2] As of February 2025, it is in the preclinical research stage of development.[1][2] Its chemical structure does not yet seem to have been disclosed, but it is said to be an indolethylamine (tryptamine).[1][4] In addition, it has been patented, though the patent does not yet appear to have been published.[6]

See also

[edit]

References

[edit]
  1. ^ a b c d "EB-003 - Enveric Biosciences". AdisInsight. 6 February 2025. Retrieved 16 February 2025.
  2. ^ a b c "Delving into the Latest Updates on EB-003(Enveric Biosciences) with Synapse". Synapse. 23 January 2025. Retrieved 16 February 2025.
  3. ^ "Pipeline – Enveric Biosciences". Enveric Biosciences. Retrieved 16 February 2025.
  4. ^ a b c "Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series". Financial Post. BusinessWire. 28 December 2023. Retrieved 16 February 2025.
  5. ^ "Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003". ENVB Stock News. 15 October 2024. Retrieved 16 February 2025.
  6. ^ "Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office". Yahoo Finance. 30 January 2025. Retrieved 16 February 2025.



Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=EB-003&oldid=1276005658"